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doi:10.1016/j.ejvs.2008.09.012Abstract Objectives: Sustained embolisation after carotid endarterectomy (CEA) predicts an
increased risk of stroke due to post-operative carotid thrombosis (POCT). Progression towards
stroke can be prevented by transcranial Doppler (TCD) directed intravenous Dextran therapy.
However, TCD monitoring is extremely labour intensive. The aim of this study was to see
whether a small cohort of high-risk patients could be identified following a 30-min period of
monitoring in the Recovery Area of the operating theatre so as to reduce the overall burden
of monitoring for the majority of patients.
Methods: Retrospective audit of prospectively acquired data in 821 patients with an accessible
temporal window who had undergone 3 h of TCD monitoring after CEA. Patients with >25
emboli in any 10 min period or large emboli distorting the waveform received Dextran.
Results: Group 1: 694 patients (85%) with 10 emboli detected within the first 30 min in the
Recovery Area of the operating theatre. Recovery: None required Dextran, none suffered
a proven ischaemic stroke and none were re-explored. Group 2: 127 patients (15%) with 11þ
emboli detected. Overall, 26 (20%) required Dextran (54% had the dose increased to control
excessive embolisation), none suffered a stroke due to POCT, but 2 suffered embolic strokes
despite Dextran. Both, however, had mitigating reasons why optimal Dextran doses could
not be administered.
Conclusions: TCDdirectedDextranhasabolished strokedue toPOCT.Ahigh-risk cohort ofpatients
requiring Dextran can be identified bymeasuring themagnitude of embolisation in the first 30 min
in Theatre Recovery. The vast majority of patients (85%) require no further monitoring.
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Despite its proven role in the management of selected
patients with symptomatic and asymptomatic disease,
carotid endarterectomy (CEA) carries a small but significant
risk of peri-operative stroke. Intra-operative stroke
(apparent upon recovery from anaesthesia) usually follows
inadvertent technical error and is virtually abolished by
a targeted strategy of intra-operative monitoring and
quality control assessment.1 By contrast, post-operative
stroke is more heterogenous in its aetiology (thromboem-
bolism, hyperperfusion syndrome, intracranial haemor-
rhage) and more difficult to prevent.
Stroke due to post-operative carotid thrombosis (POCT)
is, however, an important cause of post-operative death
and persisting neurological disability and was previously
considered both unpredictable and unpreventable.
However, a number of centres have now demonstrated that
stroke due to POCT is preceded by increasing rates of
embolisation which can be diagnosed using transcranial
Doppler (TCD) ultrasound.2e9 Evidence suggests that only
3e5% of patients develop clinically relevant post-operative
embolisation,9,10 but about 50% of these ‘higher rate
embolisers’ will suffer a thromboembolic stroke.4,11
In Leicester, patients with clinically significant post-
operative embolisation (defined as >25 emboli in any
10 min period or ‘large’ emboli distorting the middle
cerebral artery (MCA) waveform) are commenced on
intravenous Dextran therapy (20 ml bolus followed by
incremental infusion rate starting at 20 ml/h for 12 h).1 In
a series of 500 consecutive patients undergoing CEA, only
4% of patients met these criteria and required Dextran and
no-one suffered a stroke due to POCT.1
When this protocol was introduced in 1995, 6 h of TCD
monitoring was performed.10 In 1999, this was reduced to
3 h with no associated increase in thrombotic events.12
Three hours of monitoring is still, however, a considerable
burden on resources (especially as >95% of patients will not
require Dextran) and it would clearly be preferable to
reduce this to the absolute minimum. The impetus for the
current study was a growing perception amongst TCD staff
that most patients destined to require Dextran did so within
their first hour of monitoring, a phenomenon also noted by
Abbott et al.9 Accordingly, it was hypothesized that it might
be possible to identify a much smaller cohort of higher risk
patients within the first 30 min of entering the Recovery
Area of the operating theatre. Monitoring could then cease
in the remaining ‘lower risk’ patients.
Methods
A retrospective audit of prospectively acquired data from
1241 consecutive patients undergoing CEA between
1.10.1995 and 31.07.2006 was undertaken. Patients were
assessed pre-operatively in a single visit clinic where risk
factor management and Duplex assessment was performed.
Aspirin (75e150 mg daily) was continued throughout the
operative period. Duplex scanning was repeated prior to
surgery and all patients had their TCD window checked. The
basic technique of CEA (general anaesthesia, systemic
heparinisation, loupe magnification and routine shunting,patching and distal intimal tacking) has remained essen-
tially unchanged since 1988.
TCD monitoring was commenced after induction of
anaesthesia using a fixed 2 MHz head probe which was
protected by a semi-circular headguard. The surgeon and
anaesthetist aimed to ensure that mean blood flow velocity
in the middle cerebral artery (MCAV) was >15 cm/s at all
times. This threshold of 15 cm/s was chosen because Halsey
et al. has shown this to correlate with loss of cerebral
electrical activity.13 If the MCAV was <15 cm/s following
shunt insertion, the shunt was repositioned to exclude
abutment against the distal ICA lumen. If the MCAV
remained <15 cm/s, blood pressure was therapeutically
elevated by the anaesthetist. Immediately prior to patch
closure, a 5 mm space was retained adjacent to the orifice
of the external carotid artery. The shunt was removed and
all vessels back vented and irrigated with heparinised
saline. The lumen of the endarterectomy zone was then
inspected with a flexible hysteroscope (Olympus 1070-48,).
Our policy was to repair all intimal flaps >3 mm and remove
any residual thrombi from the lumen.1
Following recovery from anaesthesia, the patient was
transferred to the Recovery Area of the operating theatre
for a 3-h period of TCD monitoring. This was started as soon
as possible but there was inevitably a varying time period
between awakening the patient in theatre and restarting
monitoring in recovery. The Vascular Technologists were
experienced in TCD monitoring and used the 1995
Consensus criteria for identifying emboli.14 Previous work in
this department has shown that emboli detected in the
post-operative period are exclusively particulate.15 Dextran
40 (Pharmacia Ltd, Milton Keynes, England) was adminis-
tered to any patient who had (i) 25 emboli in any 10 min
period or (ii) emboli which distorted the MCA waveform
which suggested that they were large. This threshold of
25 emboli per 10-min period was based on work from
Gaunt’s pilot study.11 Intravenous Dextran was adminis-
tered as a 20 ml bolus and then 20 ml/h, increased stepwise
every 10 min to a maximum of 50 ml/h if there was no
reduction in the rate of embolisation. Once the rate of
embolisation stabilised or reduced, Dextran was continued
at that dose for a further 12 h.
Definition of post-operative stroke
Any new neurological deficit lasting more than 24 h and
which occurred within 30 days of CEA was defined as a post-
operative stroke. Where-ever possible, the likeliest cause
of the stroke was determined by autopsy and/or CT scan-
ning, Duplex imaging of the extracranial carotid circulation
and transcranial Doppler insonation of flow patterns in the
circle of Willis. For the purposes of this study, a post-
operative stroke was attributed to MCA embolisation from
the endarterectomy zone if there was a patent ICA on
Duplex imaging, no evidence of a recent myocardial
infarction, but a focal area of infarction in the ipsilateral
MCA territory irrespective of whether TCD had demon-
strated post-operative embolisation. Stroke due to post-
operative carotid thrombosis (POCT) was diagnosed where
re-exploration and/or Duplex imaging suggested carotid
thrombosis. A diagnosis of hyperperfusion syndrome was
made in patients who had presented with a new
Table 1 Magnitude of embolisation detected in the first
30 min of monitoring in Operating Room Recovery
No of emboli in
first 30 min of
nZ (%) Number going
on to receive
Embolisation After Carotid Endarterectomy 3neurological deficit preceded by either worsening head-
aches and/or seizures in the absence of embolisation on
TCD or haemorrhage on CT scanning. An ‘unknown’ aeti-
ology was documented in patients who had no evidence of
a cardioembolic source and who had also undergone
a normal CT scan, extracranial Duplex scan and TCD study.
Results
1241 Patients underwent CEA between 1.10.95 and
31.07.06, of whom 1143 (92%) had an accessible acoustic
window to enable TCD monitoring. Although all 1143
patients underwent at least 3 h of post-operative moni-
toring, only 821 patients (72%) had accurate documentation
of the exact amount of embolisation in the first 30 min after
monitoring started in the Recovery Area of the operating
theatre. Overall, only 26 patients (3.2%) received Dextran
according to the protocol. Two other patients received
Dextran immediately following restoration of flow (i.e.
outwith unit guidelines) at the specific request of the
operating surgeon. These two ‘off protocol’ patients were
excluded from analyses.
It was not possible to predict patients destined to
require post-operative Dextran based on the magnitude of
embolisation detected between the time of final flow
restoration and removal of the surgical drapes. Twelve of
26 patients destined to receive Dextran had no emboli
detected during this period, 11/26 had 1e10 emboli, while
only 3 had >10 emboli detected.
Fig. 1 details the cumulative delay from the patient
starting TCD monitoring in the Recovery Area of the oper-
ating theatre to starting Dextran therapy (26 patients).
Note that 50% of Dextran patients started therapy within
30 min of arriving in recovery. This yield increased to 80% at
60 min and 90% at 90 min. Accordingly, reducing the ‘fixed’
period of post-operative monitoring to 60 min for all
patients would reduce the burden of monitoring (overall) by
2 h, but 20% of patients destined to require Dextran would
have been missed. Increasing the period of monitoring to
90 min would identify 90% of patients destined to require
Dextran, but would not significantly reduce the overall
burden of monitoring. The vast majority of patients would
still continue to be monitored for an unnecessarily long
time period. Accordingly, this study showed no evidence
that simply adopting a shorter fixed time period for
everyone (e.g. 30, 60 or 90 min) with no additional%
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Figure 1 Cumulative time from onset of TCD monitoring in
Theatre Recovery to starting Dextran in 26 patients with high
rate embolisation.discriminating factor (e.g. embolus count) was beneficial to
patients.
Table 1 details the number of emboli detected within
the first 30 min of monitoring in the Recovery Area of the
operating theatre, together with the number of patients
who went on to receive Dextran. The majority of patients
(424/821 (52%)) had no emboli detected during this 30 min
period and none required Dextran. Two hundred and
seventy patients (33%) had 1e10 emboli detected and
(again) none went on to require Dextran. However, 2/44
patients (4.5%) with 11e20 emboli detected in the first
30 min subsequently developed high grade embolisation
and required Dextran. As can be seen (Table 1), an
increasing proportion of patients with >20 emboli detected
in the first 30 min in Operating Room Recovery went on to
receive Dextran.
Table 1 suggests that quantifying the magnitude of
embolisation in the first 30 min might identify patients at
lowest risk of developing significant post-operative embo-
lisation in whom monitoring could be terminated early.
Accordingly, the patient cohort was divided into two
subgroups; Group 1 (nZ 694) included patients who had
0e10 emboli detected in the first 30 min in the Recovery
Area of the operating theatre, while Group 2 (nZ 127)
comprised patients with 11þ emboli detected. No patient
in Group 1 went on to require Dextran. In Group 2, 26/127
patients (20%) went on to receive Dextran therapy, the dose
being increased in 14 (54%) in order to control the rate of
embolisation.
Twenty-one patients (2.6%) either died or suffered
a stroke within 30 days having made an uneventful recovery
from anaesthesia. Table 2 summarises the cause of these
events, stratified for the magnitude of embolisation in the
first 30 min in the Recovery Area of the operating theatre.
Fifteen patients in Group 1 (2.2%) either died or suffered
a stroke. Four events were cardiac in origin, six were
haemorrhagic, while three followed the hyperperfusion
syndrome. Two strokes were classed as being ‘unknown’ in
aetiology. These patients had undergone a normal CT scan,
normal TCD study and a normal Duplex scan. While focalmonitoring in recovery Dextran in 3 h
0 424 (52%) 0/424
1e10 270 (33%) 0/270
11e20 44 (5.4%) 2/44
21e30 30 (3.7%) 1/30
31e40 18 (2.2%) 5/18
41e50 9 (1.1%) 1/9
51e60 7 (0.9%) 4/7
61e70 6 (0.7%) 1/6
71e80 3 (0.4%) 2/3
81e90 2 (0.2%) 2/2
91e100 0 (0.0%) 0/0
>100 8 (1.0%) 8/8
821 (100%) 26/821
Table 2 30-Day death and stroke rate in patients who made a normal recovery from anaesthesia after carotid endarterec-
tomy: stratified for magnitude of embolisation in first 30 min in Operating Room Recovery
Post-operative deaths Post-operative disabling strokes Post-operative non-disabling strokes
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
<10 Emboli >10 Emboli <10 Emboli >10 Emboli <10 Emboli >10 Emboli
15 h Cardiac failure 5d Cardiac arrest 30 h ICH 3 h MCA embolisma 18 h Lentiform ICHe 3d Hyperperfusion
2d ICH 6d Brainstem strokea 2d Unknownd 1 h MCA embolisma 24 h Hyperperfusion
10d Cardiac arrest 9d ICH 3d Cardiac arrestc 3d Hyperperfusion
17d Cardiac failure 3d Bleed into metsb 6d Hyperperfusion
23d ICH 7d Bleed into infarct
14d unknownd
4/694 (0.6%) 3/127 (2.4%) 5/694 (0.7%) 2/127 (1.6%) 6/694 (0.9%) 1/127 (0.8%)
ICHZ intracranial haemorrhage.
a Patient received Dextran.
b MRI scan revealed haemorrhage into diffuse brain metastases (pre-op CT scan reported normal).
c Patient suffered a haemodynamic stroke after a cardiac arrest.
d CT scan, Duplex and TCD normal: no cause identified.
e Bleed into lentiform nucleus after hypertensive crisis.
4 R.Y. Sharpe et al.embolisation cannot be completely excluded, it is impor-
tant to note that no patient in Group 1 suffered a stroke
due to POCT and no one required re-exploration. None of
the Group 1 patients received Dextran.
Six patients in Group 2 (4.7%) died or suffered a post-
operative stroke. One followed a cardiac event, a second
followed brain haemorrhage (no Dextran given), while the
third followed the hyperperfusion syndrome. In contrast to
Group 1 patients (who suffered no proven ischaemic
neurological events), three Group 2 patients (2.4%)
suffered ischaemic neurological events, despite receiving
Dextran for very high rates of embolisation. None, however,
suffered a stroke due to carotid thrombosis (excluded on
Duplex assessment) and no Group 2 patient underwent re-
exploration. One of the three patients with an ischaemic
stroke had high grade MCA embolisation that resolved
rapidly with Dextran. However, she was readmitted with an
ischaemic brainstem stroke on day 6. It is difficult to see
how this could have been prevented. A second patient
developed severe, acute heart failure within 1 h of
recovery from anaesthesia requiring reintubation and
inotropic support. Profuse MCA embolisation was detected,
but high dose Dextran could not be administered because of
his severe heart failure. In such a situation (where higher
dose Dextran is contraindicated), our policy would normally
be to consider re-exploration. Unfortunately, this also was
contraindicated because of his parlous clinical condition.
Uncontrolled high grade embolisation continued and he
suffered a disabling stroke 3 h post-operatively. The third
patient was extremely agitated following transfer to
Theatre Recovery and it proved impossible to apply the TCD
probe for 45 min. When monitoring was started, profuse
cerebral embolisation was immediately detected. Dextran
was started, but within 15 min she suffered a disabling
stroke. In hindsight, she had probably sustained consider-
able earlier embolisation (possibly accounting for her
agitation) and the Dextran had little real prospect of
exerting any effect in such a short time period.
Finally, seven patients overall (Gp1Z 6, Gp2Z 1)
suffered an intracranial haemorrhage (nZ 5), or a bleedinto an existing infarct (nZ 1) or into cerebral metastases
(nZ 1). None of these patients received Dextran at any
time in their care.
Discussion
In a series of themed research projects, this unit has shown
that intra-operative stroke tends to follow inadvertent
technical error (usually embolism of retained luminal
thrombus whose source is bleeding from transected vasa
vasorum) which can be virtually abolished by completion
quality control assessment.1 However, stroke due to early
post-operative thromboembolism (which traditionally
complicates 2e3% of CEAs) appears to be unrelated to
technical error.16 Stroke due to POCT was previously
considered to be both unpredictable and unpreventable.
However, many centres around the world have now
demonstrated that this condition is preceded by increasing
rates of embolisation.2e9 Accordingly, patients at risk of
progressing on to stroke due to POCT can be identified using
TCD thereby allowing adjuvant pharmacotherapy (e.g.
Dextran) to be administered.1,17
This study has corroborated earlier findings that a policy
of targeted Dextran therapy reduces stroke due to
POCT.1,17 In 821 patients, only three (0.4%) suffered proven
ischaemic events following surgery, including the patient
with the brainstem event. If the latter is excluded, the
incidence of post-operative carotid territory ischaemic
stroke falls to 0.24% (a very low risk compared to previous
experience). Even if the two ‘unknown’ aetiology cases are
included, the incidence of post-operative ischaemic stroke
is still only 0.6%, a value markedly lower than was previ-
ously encountered in this unit. It is, however, conceded
that two patients did suffer definite ischaemic embolic
events despite our TCD/Dextran policy. In both situations,
however, there were mitigating circumstances that
reduced the potential effectiveness of Dextran. In the first
patient, severe acute heart failure prevented the use of
a high enough dose of Dextran to control the rate of
embolisation. In the second patient, an excessive delay to
Embolisation After Carotid Endarterectomy 5starting TCD monitoring in recovery (because of patient
restlessness) meant that profuse embolisation went
unrecognised. Accordingly, Dextran (when started) had no
realistic prospect of preventing the stroke. It is important,
however, to emphasise that no patient in this 11-year series
has required re-exploration for POCT and Table 2 indicates
that where neurological events did occur, they did not
follow carotid thrombosis. Prior to 1995, re-exploration for
post-operative thrombosis was performed in 2e3% of
patients undergoing CEA.16 These data have to be taken in
context with the natural history of patients with high rate
embolisation had they not been treated with Dextran.
Previous studies suggest that only about 3e5% of patients
will develop high rate embolisation after CEA and approx-
imately 50% will go on to suffer a thromboembolic
stroke.4,11 In the current series, 26 patients were found to
have high rate embolisation after CEA and received
Dextran. Accordingly, thirteen might have been expected
to have suffered a thromboembolic stroke, yet only three
were observed.
These results therefore suggest that a policy of TCD
directed Dextran therapy has reduced the risk of post-
operative ischaemic thromboembolic complications and,
especially, stroke due to POCT. Interestingly, there is now
emerging evidence that a similar strategy may prevent
progression on to thromboembolic stroke in patients
undergoing carotid angioplasty.18
It is accepted, however, that not all centres will be able
(or willing) to undertake 3 h of TCD monitoring, especially if
it only changes practice in <5% of patients. In 1995, a 6-h
period of monitoring was introduced as part of a research
project.10 This was reduced to 3 h in 199912 without
compromising patient safety. The current study suggests
that the optimal monitoring period can be reduced signifi-
cantly further. Fig. 1 confirms that the majority (80%) of
patients destined to require Dextran start their therapy
within the first hour of monitoring in Theatre Recovery.
Table 1 shows that patients destined to require Dextran can
be predicted from the magnitude of embolisation within
the first 30 min in Theatre Recovery. In summary, no
patient who had fewer than 10 emboli detected in the first
30 min went on to require Dextran, none required re-
exploration and none suffered a definite ischaemic neuro-
logical event in the post-operative period.
Table 3 shows how a variety of embolus thresholds might
influence monitoring practice. If a threshold of >10 emboli
in the first 30 min in Theatre Recovery was adopted,
monitoring could cease after 30 min in 85% of patients andTable 3 Yield from varying embolus thresholds for moni-
toring beyond 30 min in operating room recovery
Number of
emboli in first
30 min in recovery
Number
monitored
Number of Dextran
patients who would
have been missed
>10 127/821 (15%) 0/26 (0%)
>20 83/821 (10%) 2/26 (8%)
>30 53/821 (6%) 3/26 (12%)
>40 35/821 (4%) 8/26 (31%)
>50 26/821 (3%) 9/26 (35%)only 15% would need to be monitored for a longer period of
time. Adopting this threshold would mean that no patient
destined to require Dextran would have been missed.
Conversely, if the threshold for extended monitoring was
increased to >20 emboli, only 10% of CEA patients would
require extended monitoring, but 8% of patients destined to
require Dextran would be missed. If the threshold were
increased to >40 emboli, only 4% of patients would undergo
extended monitoring, but 35% of patients requiring Dextran
would be missed. These data therefore suggest that the
optimal policy would be to monitor everyone for 30 min in
Theatre Recovery. If the embolus count was 10, TCD
monitoring could then stop. If the count exceeded 10, then
there is a 20% chance that the patient will require Dextran
and monitoring should be extended for a further hour. If the
threshold for starting Dextran is not met during that time
period, monitoring can cease.
Unfortunately, the availability of Dextran 40 is now
being restricted in several European countries, largely
because one of the main suppliers (Baxter Healthcare,
Newbury UK) has ceased production. It is, however, still
currently manufactured as Rheomacrodex (Meda AS,
Allerod, Denmark). Paradoxically, Baxter’s decision to
withdraw production comes at a time when emerging
research suggests that Dextran may be exerting its benefi-
cial effect via an unexpected and quite novel manner.
Apart from its well documented antiplatelet and rheolog-
ical properties, Dextran also appears to cause an increase
in plasmin levels due to Dextran blockade of tPA uptake
leading to enhanced fibrinolysis, whilst also reducing
platelet adhesion to von Willebrand Factor and platelet
activation by thrombin.19 In effect, Dextran may be
exerting much of its beneficial effect in the early post-
operative period through thrombolysis.
In the event that all sources of Dextran cease, other
potential anti-thrombotic agents include S-nitro-
soglutathione, (a nitric oxide donor that inhibits platelet
adhesion and aggregation)20 and Tirofiban (intravenous
GPIIb/III platelet receptor antagonist).21 Both have been
evaluated in relatively small numbers of CEA patients, but
Tirofiban has the advantage of being commercially avail-
able (Aggrastat, Merck, Sharpe and Dohme, Hoddeson, UK)
and it has also been proposed that it confers benefit in
patients ‘resistant’ to Dextran.21
However, an alternative and, perhaps, more relevant
strategy is to question why such a small number of patients
seem to be prone to developing sustained embolisation
following CEA. A number of factors now suggest that it may
be the patient who is ‘prothrombotic’. First, patients
undergoing staged, bilateral CEA have similar rates of
embolisation after each procedure (i.e. if you were a higher
rate emboliser after the first operation, the same applied
after the second and vice versa).22 Second, in a randomised
trial, patch type (prosthetic/vein) had no influence on the
incidence of ‘high rate’ embolisers after CEA.23 Third, using
flow cytometry and platelet aggregation, the platelets of
patientswho had higher rates of embolisation after CEAwere
more sensitive to stimulation with ADP.24 A randomised trial
subsequently demonstrated that a single 75 mg dose of Clo-
pidogrel (a potent ADP inhibitor) administered the night
before surgery (in addition to normal aspirin therapy)
significantly reduced the rate of embolisation after CEA.25
>10 emboli detected in first 30 minutes? continueTCD monitoring for 60minYES
STOP TCD MONITORING >25 emboli detected in 10 min?NO
NO
embolisation falls below
25 in 10 minutes 
complete 3hr TCD monitoring &
continue Dextran for 12 hours  
embolisation falls below
25 in 10 minutes 
NO
consider imaging to exclude luminal 
thrombus or start iv Tirofiban 
NO
YES
inform Medical Team and start
Dextran with 20ml bolus and
20ml/hr iv infusion  
YES
increase Dextran by 10ml/hr
to max of 50ml/hr  
YES
Figure 2 Protocol for post-operative TCD monitoring and administration of Dextran in patients undergoing carotid endarterec-
tomy. The magnitude of embolisation in the first 30 min refers to the number of emboli detected in the first 30 min of monitoring in
Theatre Recovery.
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this unit to administer 75 mg Clopidogrel the night before
surgery (in addition to routine aspirin). An ongoing audit
will subsequently determine whether this will render post-
operative TCD monitoring obsolete. Until then, the moni-
toring protocol currently adopted in the unit is summarised
in Fig. 2. All patients currently undergo 30 min of moni-
toring in the Recovery Area of theatre. If the embolus count
is 10, TCD monitoring ceases. If the number of emboli
exceeds 10, TCD monitoring is continued for a further
60 min. If the rate of embolisation does not exceed 25 in
any 10-min period during that time, TCD monitoring then
ceases. Those few patients meeting the threshold for
Dextran therapy are monitored for 3 h. This is because over
50% of patients will require increases in their Dextran dose
in order to control the rate of embolisation. Once the
magnitude of embolisation has stabilised and is <25 in any
10 min period, the Dextran is continued for a further 12 h.
Should Dextran fail to control high rates of embolisation,
our practice would now be to consider intravenous
Tirofiban. To date, however, that has not been necessary.
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